Update: Report: Abbott prescription med unit could bring $54B

Yesterday's announcement of Abbott Laboratories' ($ABT) split into two companies has prompted speculation over whether the prescription-medicine spin-off could become a takeover target. Some analysts are saying that the company could fetch as much as $54 billion. Jeffrey Holford, a Jefferies Group analyst, names Merck ($MRK), Roche and Bayer as potential interested parties. News

Editor's Note: The headline for this story was updated and corrected to change the potential sum of a buyout of Abbott's prescription medicine business from $54 million to $54 billion.

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.